Filter by patients with: All

What is ALS Phase 3 Study VITALITY-ALS?

Category: Others

false

The ALS Phase 3 Study VITALITY-ALS clinical trial is examining the safety, tolerability and efficacy of tirasemtiv in patients with ALS. The clinical trial number is NCT02496767.

See patients taking ALS Phase 3 Study VITALITY-ALS

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Amyotrophic lateral sclerosis 8 21
Improve flexibility/strength 5 20
Decreased diaphragm strength 1 0
Diaphragm spasms 1 0
  • Major
  • Moderate
  • Slight
  • None
  • Can't tell
See all 25 patients that have used ALS Phase 3 Study VITALITY-ALS

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 1
Moderate 5
Mild 12
None 16

Commonly reported side effects and conditions associated with ALS Phase 3 Study VITALITY-ALS

Side effect Patients Percentage
Dizziness 3
Fatigue 3
Constipation 1
Drowsiness 1
Irritability 1
Jittery feeling 1

Show all 9 reported side effects

Why patients stopped taking ALS Phase 3 Study VITALITY-ALS

Multiple reasons could be selected

Reason Patients Percentage
Side effects too severe 3
Doctor's advice 2
Course of treatment ended 1
See all 5 patients who've stopped using ALS Phase 3 Study VITALITY-ALS

Duration

Stopped using ALS Phase 3 Study VITALITY-ALS

Duration Patients Percentage
Less than 1 month 1
1 - 6 months 1
6 months - 1 year 2
1 - 2 years 1
Adherence
Adherence Evaluations Percentage
Always 34
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 4
A little hard to take 17
Not at all hard to take 13
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 23
Not specified 11
Last updated:
There are no evaluations for ALS Phase 3 Study VITALITY-ALS.